Emcure signs agreement with Gilead for manufacture and supply of Lenacapavir
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
This is used to treat central diabetes insipidus and bedwetting
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The product is expected to be launched in Q3FY25
Subscribe To Our Newsletter & Stay Updated